Here are the 10-Q quarterly reports from NAYA Biosciences, Inc. (NAYA) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow NAYA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NAYA filings page.
NAYA Biosciences presents condensed results and material transactions for the period ended June 30, 2025. Consolidated revenue is reported at $3,500,839. The filing shows significant losses and non‑cash charges, including impairment charges of $1,397,353 and $14,645,069 and reported net loss amounts shown as $(5,284,858) and $(22,688,444) in the disclosed tables. The company records goodwill of $5,878,986 and finite‑lived intangible assets including tradenames and noncompetition agreements.
Liquidity and financing activity are highlighted: the company reports liquidity figures of $22.7 million and $3.8 million (as presented), an accumulated deficit of approximately $90.2 million, and net cash used in operating activities of approximately $5.3 million for the six months ended June 30, 2025 (versus $1.7 million for the prior period). Financing proceeds included approximately $8.7 million from a public offering, warrant exercises and preferred issuances; the company states it will require additional funding to meet cash needs over the next 12 months. Material business combinations and dispositions (NTI transaction and related note receivable of $4,803,175) and settlement obligations (scheduled payments totaling $5,000,000 under a term sheet) are disclosed.